![Barry Flannelly](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Barry Flannelly
Director/Board Member at
PROTARA THERAPEUTICS, INC.
Net worth: 4 M $ as of 2026-06-29
Profile
Dr. Barry P.
Flannelly is an Independent Director at PharmaEssentia Corp.
and an Independent Director at Protara Therapeutics, Inc. He is on the Board of Directors at PharmaEssentia Corp.
and Protara Therapeutics, Inc. Dr. Flannelly was previously employed as an Executive VP & General Manager-North America by Incyte Corp., a Chief Executive Officer by OSS Healthcare, Inc., a VP-Global Product Strategy & Commercial Planning by Nektar Therapeutics, a Senior Vice President-Commercial by Onyx Pharmaceuticals, Inc., and a Manager-Pharmacy Services by Johns Hopkins Oncology Center.
He also served on the board at Genomic Health, Inc. He received his undergraduate degree from Massachusetts College of Pharmacy & Health Science, an MBA from the University of Baltimore and a doctorate degree from the University of Maryland School of Pharmacy.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
INCYTE CORPORATION 0.02% | 2025-07-15 | 35,149 ( 0.02% ) | 4 M $ | 2026-06-29 |
| 2026-06-14 | 0 ( -.--% ) | - $ | 2026-06-29 |
Barry Flannelly active positions
| Companies | Position | Start |
|---|---|---|
| PROTARA THERAPEUTICS, INC. | Director/Board Member | 2020-07-22 |
Former positions of Barry Flannelly
| Companies | Position | End |
|---|---|---|
| INCYTE CORPORATION | Corporate Officer/Principal | 2025-07-30 |
| GENOMIC HEALTH, INC. | Director/Board Member | 2019-11-07 |
OSS Healthcare, Inc. | Chief Executive Officer | 2014-06-30 |
| NEKTAR THERAPEUTICS | Corporate Officer/Principal | 2013-03-31 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Corporate Officer/Principal | 2010-12-31 |
Training of Barry Flannelly
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
70
1st degree connections
10
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
Incyte Corp.
 Incyte Corp. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of proprietary therapeutics | Health Technology |
Nektar Therapeutics
 Nektar Therapeutics Pharmaceuticals: MajorHealth Technology Discovers and develops medicines in areas of high unmet medical need | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Health Technology |
Genomic Health, Inc.
 Genomic Health, Inc. Medical/Nursing ServicesHealth Services Engages in genomic-based diagnostic tests for overtreatment and optimal treatment of early stage cancer | Health Services |
Massachusetts College of Pharmacy & Health Science
 Massachusetts College of Pharmacy & Health Science Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Baltimore
 University of Baltimore Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OSS Healthcare, Inc. | |
University of Maryland School of Pharmacy
 University of Maryland School of Pharmacy Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Protara Therapeutics, Inc.
 Protara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
Johns Hopkins Oncology Center |
- Stock Market
- Insiders
- Barry Flannelly
